Abstract
Since their initial description in 1992, neurospheres have appeared in some aspect of more than a thousand published studies. Despite their ubiquitous presence in the scientific literature, there is little consensus regarding the fundamental defining characteristics of neurospheres; thus, there is little agreement about what, if anything, the neurosphere assay can tell us about the relative abundance or behavior of neural stem cells in vivo. In this review we will examine some of the common features of neurospheres, and ask if these features should be interpreted as a proxy for neural stem cells. In addition, we will discuss ways in which the neurosphere assay has been used to evaluate in vivo treatment/manipulation, and will suggest appropriate ways in which neurosphere data should be interpreted, vis-a-vis the neural stem cell. Finally, we will discuss a relatively new in vitro approach, the Neural-Colony Forming Cell Assay, which provides a more meaningful method of quantifying bona fide neural stem cells without conflating them with more growth-restricted progenitor cells.
Keywords: Neurosphere, neural stem cell, stem cell assay
Current Pharmaceutical Biotechnology
Title: Using the Neurosphere Assay to Quantify Neural Stem Cells In Vivo
Volume: 8 Issue: 3
Author(s): Gregory P. Marshall, Brent A. Reynolds and Eric D. Laywell
Affiliation:
Keywords: Neurosphere, neural stem cell, stem cell assay
Abstract: Since their initial description in 1992, neurospheres have appeared in some aspect of more than a thousand published studies. Despite their ubiquitous presence in the scientific literature, there is little consensus regarding the fundamental defining characteristics of neurospheres; thus, there is little agreement about what, if anything, the neurosphere assay can tell us about the relative abundance or behavior of neural stem cells in vivo. In this review we will examine some of the common features of neurospheres, and ask if these features should be interpreted as a proxy for neural stem cells. In addition, we will discuss ways in which the neurosphere assay has been used to evaluate in vivo treatment/manipulation, and will suggest appropriate ways in which neurosphere data should be interpreted, vis-a-vis the neural stem cell. Finally, we will discuss a relatively new in vitro approach, the Neural-Colony Forming Cell Assay, which provides a more meaningful method of quantifying bona fide neural stem cells without conflating them with more growth-restricted progenitor cells.
Export Options
About this article
Cite this article as:
Gregory P. Marshall , Brent A. Reynolds and Eric D. Laywell , Using the Neurosphere Assay to Quantify Neural Stem Cells In Vivo, Current Pharmaceutical Biotechnology 2007; 8 (3) . https://dx.doi.org/10.2174/138920107780906559
DOI https://dx.doi.org/10.2174/138920107780906559 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hypoxia-Inducible Factor-1 (HIF-1): A Potential Target for Intervention in Ocular Neovascular Diseases
Current Drug Targets Renal Cell Carcinoma Cancer Stem Cells as Therapeutic Targets
Current Signal Transduction Therapy Nanoparticle Systems Modulating Myeloid-Derived Suppressor Cells for Cancer Immunotherapy
Current Topics in Medicinal Chemistry RAGE and RAGE Ligands in Cancer
Current Molecular Medicine High Therapeutic Potential for Systemic Delivery of a Liposomeconjugated Herpes Simplex Virus
Current Cancer Drug Targets Ex Vivo Liver – Directed Gene Therapy for the Treatment of Metabolic Diseases: Advances in Hepatocyte Transplantation and Retroviral Vectors
Current Gene Therapy Antiangiogenesis and Radiotherapy: What Is the Role of Combined Modality Treatment?
Current Medicinal Chemistry - Anti-Cancer Agents Ex Vivo Gene Transfer for Improvement of Transplanted Pancreatic Islet Viability and Function
Current Pharmaceutical Design The Expanding Universe of Neurotrophic Factors: Therapeutic Potential in Aging and Age-Associated Disorders
Current Pharmaceutical Design A Review on Deep Learning Architecture and Methods for MRI Brain Tumour Segmentation
Current Medical Imaging Isolation, Structural Determination, and Evaluation of the Biological Activity of 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol [20(S)-25-OCH3-PPD], a Novel Natural Product from Panax notoginseng
Medicinal Chemistry Convection Enhanced Drug Delivery of Novel Therapeutic Agents to Malignant Brain Tumors
Current Drug Delivery NK Cell Receptor and MHC Gene Polymorphisms, Potential Relevance in Malignancies
Current Cancer Therapy Reviews The Impacts of Non-coding RNAs and N<sup>6</sup>-Methyladenosine on Cancer: Past, Present and Future
Current Cancer Drug Targets Nutritional Attributes and Health Application of Seabuckthorn (<i>Hippophae rhamnoides</i> L.) – A Review
Current Nutrition & Food Science Subject Index to Volume 3
Current Gene Therapy The Proteolytic Activation of Angiogenic and Lymphangiogenic Growth Factors in Cancer – Its Potential Relevance for Therapeutics and Diagnostics
Current Medicinal Chemistry Protein Kinase C and Prostate Carcinogenesis: Targeting the Cell Cycle and Apoptotic Mechanisms
Current Drug Targets Arsenic Trioxide Targets miR-125b in Glioma Cells
Current Pharmaceutical Design Aflibercept (VEGF-TRAP): The Next Anti-VEGF Drug
Inflammation & Allergy - Drug Targets (Discontinued)